To investigate the in vitro anti-cancer efficacy of the CDK9-specific inhibitor, DRB, MCF-7 and T-47D breast cancer cells were exposed to various concentrations of DRB for up to 72 h, and cell viability was determined by MTT assays. This evidence concerns the gene CDK9 and breast cancer.